Novartis AG (NVSEF) Free cash flow 2016–2025
Novartis AG (NVSEF) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$17.6BFY2025 · since FY2016: $9.6B → $17.6B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $17.6B | +8.3% |
| FY2024 | $16.3B | +21.3% |
| FY2023 | $13.4B | +0.6% |
| FY2022 | $13.3B | -4.9% |
| FY2021 | $14.0B | +13.2% |
| FY2020 | $12.4B | +1.1% |
| FY2019 | $12.2B | -5.9% |
| FY2018 | $13.0B | +15.2% |
| FY2017 | $11.3B | +17.5% |
| FY2016 | $9.6B | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NVSEF financial trends
NVSEF RevenueNVSEF Net incomeNVSEF Net marginNVSEF Gross profitNVSEF Gross marginNVSEF Operating incomeNVSEF Operating marginNVSEF Operating cash flowNVSEF Capital expendituresNVSEF Return on equityNVSEF Stock buybacksNVSEF Dividends paidNVSEF Total assetsNVSEF Total liabilitiesNVSEF Shareholders’ equityNVSEF overview →